Sonoma Pharmaceuticals, Inc. (SNOA)

NCM – Real Time Price. Currency in USD

1.36

-0.01 (-0.37%)

Market open: Aug 12, 2026, 10:16 AM EDT

1.38

+0.01 (0.73%)

Previous after-hours: Aug 11, 2026, 7:41 PM EDT

06.08.2026

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared to the prior-year quarter Gross margin expanded to 40% as operating expenses remained stable FDA clearance and new global distributors support continued commercial growth BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2026. "Our first quarter results demonstrate that Sonoma has reached an important inflection point," said Amy Trombly, CEO of Sonoma.

06.08.2026

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) on Thursday posted a first-quarter loss of 9 cents per share compared to a loss of 76 cents a year ago.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Sonoma Pharmaceuticals, Inc. (SNOA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Videos

No Data

Press releases

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Videos

No Data

Press releases

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Search stocks

Sonoma Pharmaceuticals, Inc. (SNOA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Videos

No Data

Press releases

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Videos

No Data

Press releases

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA